Vilon vs Liraglutide
Side-by-side comparison of key properties, dosing, and research.
Immune SupportAnti-Aging & Longevity
VilonGLP-1 / Weight Loss AgonistsFat Loss & Metabolic
Liraglutide- Summary
- Vilon is a synthetic dipeptide (Lys-Glu) derived from the thymus gland extract Thymalin. The shortest immune-regulatory peptide known, Vilon modulates T-cell and NK-cell function, extends lifespan in animal models, and shows epigenetic anti-aging activity. It is one of the Khavinson peptide bioregulators.
- Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
- Half-Life
- Very short as a free dipeptide; effects mediated via gene regulation
- ~13 hours (once-daily dosing)
- Admin Route
- SubQ, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 1–2 mg SC daily or 5–10 mg oral daily
- Start 0.6 mg, titrate to 3 mg
- Frequency
- Once daily
- Once daily
- Key Benefits
- Immune system modulation and restoration
- Lifespan extension (30–40% in animal studies)
- T-cell and NK-cell activation
- Epigenetic anti-aging activity
- Reduces oxidative stress markers
- Antioxidant gene upregulation
- May prevent age-related immune senescence
- Anti-tumor immune surveillance
- Promotes weight loss (5–10% average)
- Reduces appetite and caloric intake
- Improves blood glucose control (HbA1c reduction)
- Reduces cardiovascular events in T2DM (LEADER trial)
- Slows gastric emptying
- FDA-approved for T2DM and chronic weight management
- Cardioprotective effects shown in clinical trials
- May improve fatty liver (NAFLD/NASH)
- Side Effects
- Excellent safety profile, decades of Russian clinical use
- Rare: mild injection site reaction
- Very rare: mild allergic reaction
- Nausea (very common, especially initially)
- Vomiting
- Diarrhea or constipation
- Decreased appetite
- +5 more
- Stacks With
- —
- —